Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report)'s share price fell 0.1% during trading on Thursday . The company traded as low as $10.44 and last traded at $10.44. 1,200 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 45,322 shares. The stock had previously closed at $10.45.
Oaktree Acquisition Corp. III Life Sciences Trading Down 0.3%
The business has a fifty day moving average price of $10.48.
Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences
A number of large investors have recently added to or reduced their stakes in the company. Kepos Capital LP bought a new position in Oaktree Acquisition Corp. III Life Sciences in the first quarter worth about $563,000. Picton Mahoney Asset Management purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the first quarter worth about $767,000. HighTower Advisors LLC purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the first quarter worth about $1,401,000. DLD Asset Management LP grew its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 100.0% during the first quarter. DLD Asset Management LP now owns 350,000 shares of the company's stock worth $3,580,000 after acquiring an additional 175,000 shares during the last quarter. Finally, K2 Principal Fund L.P. purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the fourth quarter worth about $1,945,000.
Oaktree Acquisition Corp. III Life Sciences Company Profile
(
Get Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Read More
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
